Sigyn Therapeutics, Inc. 是一家处于开发阶段的公司,致力于创造解决全球健康未满足需求的治疗方案。公司总部位于加利福尼亚州比佛利山庄,目前拥有4名全职员工。该公司于2016年1月28日上市。公司专注于开发应对全球健康领域未满足需求的治疗方案。其候选产品Sigyn疗法是一种广谱血液净化技术,旨在治疗与病原体相关的炎症性疾病。其治疗适应症包括内毒素血症、终末期肾病(透析)患者的炎症、脓毒症(医院死亡原因之一)、社区获得性肺炎(传染病死亡原因之一)以及新兴的大流行威胁。Sigyn疗法是一种一次性使用的可弃置设备,可在全球现有的血液透析和连续性肾脏替代治疗(CRRT)机器基础设施上部署使用。公司的研发管线还包括一种癌症治疗系统,由ChemoPrep组成,用于增强化疗药物在肿瘤部位的递送,以及ChemoPure,用于降低治疗毒性并抑制癌症转移的扩散。
SIGY stock price ended at $0.04 on 星期二, after rising 0.00%
On the latest trading day May 19, 2026, the stock price of SIGY rose by 0.00%, climbing from $0.04 to $0.04. Throughout the session, the stock experienced a volatility of 0.00%, with prices fluctuating between a daily low of $0.04 and a high of $0.04. Alongside this price increase, trading volume also rose by 31.8K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 100 shares were traded, amounting to a market value of approximately $64.4K.